1. What Is the Oral Drug Delivery Market?
The Oral Drug Delivery Market covers the formulation technologies, dosage forms, and controlled release systems that optimise the administration, absorption, bioavailability, and therapeutic effect of medicines taken by mouth. The market spans immediate-release tablets and capsules that dissolve quickly in the gastrointestinal tract, modified-release formulations that extend drug absorption over hours to days, and specialised oral delivery systems. Specialised systems include orally disintegrating tablets, mucoadhesive buccal films, and oral biologic delivery technologies that overcome the gastrointestinal barriers that large molecule drugs encounter. Oral drug delivery formulation uses the excipient chemistry of polymers, surfactants, lipids, and wetting agents that stabilise the drug substance in the dosage form. These excipients enhance the aqueous solubility of poorly soluble drug candidates using amorphous solid dispersion, nano-crystallisation, and lipid-based drug delivery systems. They also control the drug release rate using the polymer matrix, the coating, or the osmotic pump that the product design determines for the target pharmacokinetic profile. Pharmaceutical formulation teams use these technologies to produce the oral drug delivery formulations that the majority of marketed pharmaceutical products use as the preferred route of administration. The oral drug delivery market is being advanced by ionic liquid technology and permeation enhancer systems that enable the oral delivery of peptide and small protein drugs. The oral GLP-1 for obesity and diabetes and other gastrointestinal permeation approaches are overcoming the enzymatic degradation and poor mucosal permeability of biological molecules that historically prevented systemic bioavailability from oral protein administration.
2. Oral Drug Delivery Market Size & Forecast
3. Emerging Technologies
- Amorphous solid dispersion technology using hot melt extrusion or spray-dried dispersion converts the poorly water-soluble crystalline drug into an amorphous form dispersed in the hydrophilic polymer matrix. This increases the apparent aqueous solubility by 10 to 100-fold through the supersaturation effect created at the intestinal absorption site. The approach enables the oral bioavailability of the BCS Class II and Class IV drug candidates that low aqueous solubility limits to sub-therapeutic plasma levels in crystalline formulation.
- Oral peptide drug delivery using ionic liquid technology protects semaglutide from pepsin and trypsin degradation and transiently increases the gastric mucosal permeability. The permeability increase occurs at the local concentration that the co-formulated carrier creates in the gastric mucosa. The approach enables approximately 1 percent oral bioavailability that the oral semaglutide tablet achieves. This represents the breakthrough that demonstrates the feasibility of oral peptide delivery for GLP-1 drugs that subcutaneous injection previously required.
- Extended-release abuse-deterrent formulation uses physical and chemical barriers that the polymer matrix, the antagonist inclusion, and the aversion agent create to resist the crushing, cutting, dissolving, and extraction that the opioid abuser would attempt. This conversion would shift the extended-release formulation to the immediate-release dose that achieves the euphoric blood concentration that the controlled-release design prevents. Physical deterrence reduces the abuse risk while preserving the therapeutic benefit for the legitimate patient.
- Gastric retentive oral drug delivery uses the expandable polymer system that unfolds in the stomach to exceed the 13 millimetre pyloric diameter that prevents the expanded form from passing into the small intestine. The gastric retention enables 24-hour drug release at the gastric absorption window for drugs with the narrow absorption window in the upper gastrointestinal tract. Drugs that are poorly absorbed from the lower GI tract benefit most from this delivery approach.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Drug Discovery Market.
4. Key Market Opportunity
Material revenue potential in the Oral Drug Delivery market comes from modified release and controlled delivery technologies, where extending drug action and reducing dosing frequency improve both therapeutic outcomes and patient adherence in chronic disease management. Technology providers and CDMO partners enabling modified release formulations capture this innovation demand. Adjacent demand centers on oral oncology formulation supporting targeted small molecule launches. As modified release and oral oncology formulation grow, the addressable opportunity is expanding from standard tablet manufacturing toward advanced controlled delivery and emerging oral biologic formulations.
5. Top Companies in the Oral Drug Delivery Market
The following organisations hold leading positions in the Oral Drug Delivery Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novo Holdings
- Lonza
- Evonik Industries
- Capsugel (Lonza)
- ACG Worldwide
- Patheon (Thermo Fisher)
- Aenova Group
- BASF
6. Market Segmentation
The Oral Drug Delivery Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Technology | Immediate Release Modified Release Controlled Release Gastroretentive |
| By Formulation | Tablet Capsule Oral Film Liquid |
| By Application | CNS Oncology Cardiovascular Metabolic |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Oral Drug Delivery Market trajectory over the forecast period:
Amorphous Solid Dispersion Hot Melt Extrusion and Spray-Dried Dispersion Increasing Aqueous Solubility 10 to 100-Fold Through Supersaturation Is Enabling Oral Bioavailability of BCS Class II and IV Drug Candidates That Crystalline Formulation Cannot Achieve at Therapeutic Levels.Novo Nordisk's sodium N-capryloyl-8-aminocaprylate absorption enhancer enabling oral semaglutide Rybelsus demonstrates that peptide oral bioavailability challenges can be pharmacologically overcome for commercial GLP-1 application, achieving 1% oral bioavailability sufficient for therapeutic efficacy at approved 7-14 mg doses. Oral GLP-1 agonists from Eli Lilly's orforglipron small-molecule approach and next-generation oral semaglutide with improved fasting-requirement pharmacokinetics represent the competitive pressure driving Novo Nordisk's oral formulation innovation. The market opportunity for oral biologics extends beyond GLP-1 to insulin, parathyroid hormone, and antibody fragments where oral delivery would transform the largest injectable-dependent therapeutic classes into tablet-based medications that remove injection barriers limiting patient uptake.
Ionic Liquid SNAC Carrier Enabling 1 Percent Oral Semaglutide Bioavailability in Rybelsus by Protecting Peptide From GI Degradation and Transiently Enhancing Gastric Mucosal Permeability Is the Breakthrough That Makes Oral Peptide Delivery Commercially Viable.The commercial lifecycle management strategy of converting immediate-release twice-daily or three-times-daily drugs to extended-release once-daily formulations before patent expiry has been applied to metformin ER, metoprolol succinate, quetiapine XR, and naltrexone ER, extending branded product lifecycle by 3-5 years while providing genuine clinical advantages in adherence that justify the patent extension. Osmotic drug delivery OROS technology from Alza Pharmaceuticals now Janssen, and SODAS multi-particulate spheroidal oral drug absorption systems from Shire, represent the manufacturing platform innovations that enable the controlled release kinetics underlying the clinical convenience claim. FDA's abuse-deterrent extended-release classification for opioids including OxyContin reformulation requiring physical and chemical manipulation resistance has created a distinct regulatory and commercial category where extended-release formulations provide abuse resistance alongside prolonged analgesia.
Gastric Retentive Expandable Polymer Systems Exceeding 13mm Pyloric Diameter to Achieve 24-Hour Gastric Retention Are Enabling Sustained Drug Release at the Upper GI Absorption Window for Drugs With Narrow Intestinal Absorption Windows.Ferring Pharmaceuticals's budesonide MMX multi-matrix system achieves colonic budesonide delivery from an Eudragit polymer matrix releasing at pH above 7 that delivers steroid to the inflamed colonic mucosa of ulcerative colitis patients without the systemic absorption that causes adrenal suppression from systemic budesonide. Calliditas Therapeutics's Tarpeyo budesonide delayed-release capsule achieves Peyer's patch ileal delivery that reduces galactose-deficient IgA1 production in IgA nephropathy through a similar ileal pH-trigger mechanism that delivers budesonide to the submucosal immune cells without systemic immunosuppression. The regulatory precedent for site-specific formulation-based indication differentiation, where a drug approved systemically receives a new indication through formulation-directed local delivery that the systemic form cannot achieve without unacceptable toxicity, is informing drug development strategies for enteric nervous system targets and gastrointestinal mucosal immune disease.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By technology, the extended-release and modified-release segment dominated the Oral Drug Delivery Market in 2025, as polymer matrix and osmotic pump technologies from Catalent and Lonza anchored sustained-delivery formulations across cardiovascular, psychiatric, and pain therapy, generating the largest share of advanced oral delivery revenue.
By formulation, the lipid nanoparticle and nanotechnology segment is projected to register the highest growth rate through 2034, as delivery platforms pioneered for mRNA vaccines expand into oral administration of biologics and small-molecule drugs with poor aqueous solubility.
9. Regional Analysis
Regional demand patterns across the Oral Drug Delivery Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Oral Drug Delivery Market in 2025, accounting for approximately 48% of global revenue, attributed to the US pharmaceutical market's preference for oral formulations and the concentration of oral drug delivery technology companies and CDMOs. Moreover, oral oncology and specialty drug formulation investment is advanced in North America. In addition, modified release technology innovation is attributed to US and European companies. Regional leadership is due to this combination of market scale and technology concentration.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Oral Drug Delivery Market through 2034, driven by the large generic drug manufacturing base in India producing oral formulations for global markets and expanding domestic pharmaceutical consumption in China and India. The region is also witnessing CDMO oral formulation capacity growth. Moreover, chronic disease oral drug demand is expanding with healthcare access. The combination of these demand drivers and manufacturing scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Oral Drug Delivery Market was valued at USD 96.78 Bn in 2025 and is projected to reach USD 180.94 Bn by 2034, growing at a CAGR of 7.2% over the 2026–2034 forecast period.
The Oral Drug Delivery Market is projected to grow at a CAGR of 7.2% from 2026 to 2034.
North America dominated the Oral Drug Delivery Market in 2025, accounting for approximately 48% of global revenue, attributed to the US pharmaceutical market's preference for oral formulations and the concentration of oral drug delivery technology companies and CDMOs.
The leading companies in the Oral Drug Delivery Market include Novo Holdings, Lonza, Evonik Industries, Capsugel (Lonza), ACG Worldwide, Patheon (Thermo Fisher), Aenova Group, BASF.
Amorphous solid dispersion hot melt extrusion and spray-dried dispersion increasing aqueous solubility 10 to 100-fold through supersaturation is enabling oral bioavailability of bcs class ii and iv drug candidates that crystalline formulation cannot achieve at therapeutic levels.
By technology, the extended-release and modified-release segment dominated the Oral Drug Delivery Market in 2025, as polymer matrix and osmotic pump technologies from Catalent and Lonza anchored sustained-delivery formulations across cardiovascular, psychiatric, and pain therapy, generating the largest share of advanced oral delivery revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.